S&P 500 Technology Sector SEC Filings — October 01, 2026

Q4 FY2026 revenue of $18.68B beat high-end guidance, with 7% local-currency growth; FY2026 adjusted EPS grew 8% to $13.97, above prior year

Director Stephen Rusckowski bought 25,000 shares at $139.35 (~$3.48M), a rare open-market purchase signaling confidence; now holds 25,390 shares

FY2027 guidance of 3%-6% local-currency revenue growth is below FY2026's 5% local-currency growth, indicating deceleration

Full-year GAAP effective tax rate rose to 25.1% from 23.7% in FY2025, a 140 bps headwind to EPS

SVP Jennifer Newstead sold 2,399 shares at $336.18 (~$806K) under a 10b5-1 plan; routine but notable given high stock price

Seven directors exercised/converted 459 RSUs each, a routine vesting pattern; no selling, indicating no insider concern

Executives awarded 92,908 Class A shares each (Glazer and Taylor) and 16,714 SARs (Buckley), aligning management with long-term performance

12 directors awarded Promised Fee Shares at $219.93 (ranging from $58.9K to $108K), routine compensation; no insider selling

Q4 free cash flow declined to $2.85B from $3.81B YoY (-25%), a significant deterioration in cash generation

DSOs rose to 50 days from 47 days YoY, indicating slower cash collection and potential revenue quality concerns

Q4 free cash flow fell 25% YoY to $2.85B, and DSOs increased 3 days to 50, signaling weaker cash conversion

FY2027 guidance of 3%-6% local-currency growth is below FY2026's 5% local-currency growth, and Health & Public Service and Products segments decelerated

Effective tax rate rose to 25.1% from 23.7%, a 140 bps headwind that could persist into FY2027

Asia Pacific Q4 revenue grew only 3% in USD, the slowest region, though local-currency growth was 7%

SVP Newstead sold $806K of stock; while under 10b5-1, it adds to insider selling pressure at high valuation

New director Frank Baker (PE background) adds expertise but no immediate operational impact; watch for strategic shifts

Large equity awards (92,908 shares each) could dilute shareholders if not offset by buybacks

Directors converting RSUs is routine, but the lack of open-market buying suggests no strong insider conviction

Director Rusckowski's $3.48M open-market purchase at $139.35 is a strong bullish signal; consider adding to positions

Q4 revenue beat high-end guidance with 7% local-currency growth; if FY2027 guidance is conservative, there is upside potential

Full-year revenue grew 6% USD/5% local currency; strong demand in AI and cloud services could drive reacceleration

Large equity awards tie executive compensation to long-term performance, aligning interests with shareholders

No insider selling despite RSU conversions; stable management confidence supports a hold thesis

New director with PE and tech expertise could drive strategic initiatives, including M&A or divestitures

The sale is pre-planned and small relative to holdings (41,992 shares remain), so it does not signal fundamental deterioration

If the tax rate reverts toward 23-24% in FY2027, EPS could see a tailwind

22 of 27 filings are insider transactions (director fee shares, RSU conversions, gifts), with no pattern of selling; the only notable buy is Oracle's director purchase, suggesting sector-wide insider confidence is stable

Accenture's FY2027 guidance (3-6% local-currency) is below FY2026 (5% local-currency), indicating a slowdown in IT services spending, which may affect peers like IBM and Cognizant

Accenture's FCF declined 25% YoY and DSOs rose, highlighting that revenue growth is not translating to cash generation—a trend to watch across the sector

Accenture's effective tax rate rose 140 bps, a common theme for multinational tech firms facing global tax changes

IBM, Fortinet, and Palantir all show routine equity awards, indicating a sector-wide reliance on stock-based compensation, which can dilute shareholders

None of the filings disclosed dividends, buybacks, or M&A, suggesting companies are conserving cash or focusing on organic investment

Q4 FY2026 earnings call scheduled; watch for commentary on FY2027 guidance, AI demand, and cash flow improvement [Date: Oct 2026]

Monitor if other insiders follow Rusckowski's purchase; additional buys would reinforce bullish sentiment [Ongoing]

Watch for further 10b5-1 sales by executives; a pattern of selling could signal valuation concerns [Ongoing]

Frank Baker's appointment effective Oct 1, 2026; monitor for strategic announcements (M&A, divestitures) in coming quarters [Q4 2026]

Watch for future large equity grants; dilution could pressure EPS if not offset by buybacks [Ongoing]

Monitor if directors begin selling after vesting; current conversions are routine but selling would be a red flag [Ongoing]

If DSOs continue to rise in Q1 FY2027, it could indicate revenue quality issues; watch next quarterly report [Jan 2027]